1
|
Lescop C, Brotschi C, Williams JT, Sager CP, Birker M, Morrison K, Froidevaux S, Delahaye S, Nayler O, Bolli MH. Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold. J Med Chem 2024; 67:2379-2396. [PMID: 38349223 DOI: 10.1021/acs.jmedchem.3c01826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2024]
Abstract
Lysophosphatidic acid receptor 1 (LPAR1) antagonists show promise as potentially novel antifibrotic treatments. In a human LPAR1 β-arrestin recruitment-based high-throughput screening campaign, we identified urea 19 as a hit with a LPAR1 IC50 value of 5.0 μM. Hit-to-lead activities revealed that one of the urea nitrogen atoms can be replaced by carbon and establish the corresponding phenylacetic amide as a lead structure for further optimization. Medicinal chemistry efforts led to the discovery of piperidine 18 as a potent and selective LPAR1 antagonist with oral activity in a mouse model of LPA-induced skin vascular leakage. The molecular scaffold of 18 shares no obvious structural similarity with any other LPAR1 antagonist disclosed so far.
Collapse
Affiliation(s)
- Cyrille Lescop
- DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Christine Brotschi
- DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Jodi T Williams
- DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Christoph P Sager
- DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Magdalena Birker
- DD Biology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Keith Morrison
- DD Pharmacology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Sylvie Froidevaux
- DD Pharmacology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Stéphane Delahaye
- Preclinical DMPK, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Oliver Nayler
- DD Biology, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Martin H Bolli
- DD Chemistry, Idorsia Pharmaceuticals, Ltd, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| |
Collapse
|
2
|
Alshamari AK, Al-Qudah MA, Hamadeh F, Al-Momani LA, Abu-Orabi ST. Synthesis, Characterization, Antimicrobial and Antioxidant Activities of
1,2,4-triazolyl-isoxazole Moieties via Dehydration Reactions of Carbohydrazides. LETT ORG CHEM 2022. [DOI: 10.2174/1570178618666210531095246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Abstract:
For the reason of distinct place in the field of medicinal and pharmaceutical chemistry of
1,2,4-triazole derivatives, a new class of fused 1,2,4-triazolyl-isoxazole moieties was prepared from 3-
(2,4,6-trimethoxyphenyl)isoxazolo-4,5-bis[carbonyl-(4̍-phenyl) thiosemicarbazide via dehydration reactions
of carbohydrazides by using the appropriate chemical reagents. The structures of the compounds
were elucidated by both elemental and spectral (IR, NMR and MS) analyses. The in vitro antioxidant
activity of the new compounds was determined by free radical scavenging and metal chelating
activity. All the synthesized compounds showed good activity according to free radical scavenging and
metal chelating activity compared with standards. The new compounds were screened in vitro antibacterial
activity against three gram-positive bacteria and three gram-negative bacteria.
Collapse
Affiliation(s)
- Asma K. Alshamari
- Department of Chemistry, Faculty of Science, University of Ha\'il, P.O. Box 2440, Saudi Arabia
| | - Mahmoud A. Al-Qudah
- Department of Chemistry,
Faculty of Science, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan
| | - Fedaa Hamadeh
- Department of Chemistry,
Faculty of Science, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan
| | - Lo’ay A. Al-Momani
- Department of Chemistry, Tafila
Technical University, P.O. Box 179, Tafila 66110, Jordan
| | - Sultan T. Abu-Orabi
- Department of Chemistry,
Faculty of Science, Yarmouk University, P.O. Box 566, Irbid 21163, Jordan
- Department of Medical Analysis, Faculty of Science, Tishk
International University, Erbil, KRG, Iraq
| |
Collapse
|
3
|
Liu W, Hopkins AM, Hou J. The development of modulators for lysophosphatidic acid receptors: A comprehensive review. Bioorg Chem 2021; 117:105386. [PMID: 34695732 DOI: 10.1016/j.bioorg.2021.105386] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Revised: 09/03/2021] [Accepted: 09/25/2021] [Indexed: 12/23/2022]
Abstract
Lysophosphatidic acids (LPAs) are bioactive phospholipids implicated in a wide range of cellular activities that regulate a diverse array of biological functions. They recognize two types of G protein-coupled receptors (LPARs): LPA1-3 receptors and LPA4-6 receptors that belong to the endothelial gene (EDG) family and non-endothelial gene family, respectively. In recent years, the LPA signaling pathway has captured an increasing amount of attention because of its involvement in various diseases, such as idiopathic pulmonary fibrosis, cancers, cardiovascular diseases and neuropathic pain, making it a promising target for drug development. While no drugs targeting LPARs have been approved by the FDA thus far, at least three antagonists have entered phase Ⅱ clinical trials for idiopathic pulmonary fibrosis (BMS-986020 and BMS-986278) and systemic sclerosis (SAR100842), and one radioligand (BMT-136088/18F-BMS-986327) has entered phase Ⅰ clinical trials for positron emission tomography (PET) imaging of idiopathic pulmonary fibrosis. This article provides an extensive review on the current status of ligand development targeting LPA receptors to modulate LPA signaling and their therapeutic potential in various diseases.
Collapse
Affiliation(s)
- Wenjie Liu
- Department of Chemistry, Lakehead University and Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada
| | - Austin M Hopkins
- Department of Chemistry, Lakehead University and Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada
| | - Jinqiang Hou
- Department of Chemistry, Lakehead University and Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON P7B 6V4, Canada.
| |
Collapse
|
4
|
Lentini NA, Schroeder CM, Harmon NM, Huang X, Schladetsch MA, Foust BJ, Poe MM, Hsiao CHC, Wiemer AJ, Wiemer DF. Synthesis and Metabolism of BTN3A1 Ligands: Studies on Modifications of the Allylic Alcohol. ACS Med Chem Lett 2021; 12:136-142. [PMID: 33488975 DOI: 10.1021/acsmedchemlett.0c00586] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Accepted: 11/30/2020] [Indexed: 12/26/2022] Open
Abstract
(E)-4-Hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP) and its phosphonate analogs are potent phosphoantigens. HMBPP contains an (E)-allylic alcohol which interacts with the molecular target BTN3A1 giving an antigenic signal to activate Vγ9Vδ2 T cells. As probes of BTN3A1 function, we prepared prodrug derivatives of the HMBPP analog C-HMBP that lack the (E)-allylic alcohol or have modified it to an aldehyde or aldoxime and evaluated their biological activity. Removal of the alcohol completely abrogates phosphoantigenicity in these compounds while the aldoxime modification decreases potency relative to the (E)-allylic alcohol form. However, homoprenyl derivatives oxidized to an aldehyde stimulate Vγ9Vδ2 T cells at nanomolar concentrations. Selection of phosphonate protecting groups (i.e., prodrug forms) impacts the potency of phosphoantigen aldehydes, with mixed aryl acyloxyalkyl forms exhibiting superior activity relative to aryl amidate forms. The activity correlates with the cellular reduction of the aldehyde to the alcohol form. Thus, the functionality on this ligand framework can be altered concurrently with phosphonate protection to promote cellular transformation to highly potent phosphoantigens.
Collapse
Affiliation(s)
- Nicholas A. Lentini
- Department of Chemistry, University of Iowa, Iowa City, Iowa 52242-1294, United States
| | - Chloe M. Schroeder
- Department of Chemistry, University of Iowa, Iowa City, Iowa 52242-1294, United States
| | - Nyema M. Harmon
- Department of Chemistry, University of Iowa, Iowa City, Iowa 52242-1294, United States
| | - Xueting Huang
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut 06269-3092,United States
| | - Megan A. Schladetsch
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut 06269-3092,United States
| | - Benjamin J. Foust
- Department of Chemistry, University of Iowa, Iowa City, Iowa 52242-1294, United States
| | - Michael M. Poe
- Department of Chemistry, Western Michigan University, Kalamazoo, Michigan 49008-5413, United States
| | - Chia-Hung Christine Hsiao
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut 06269-3092,United States
| | - Andrew J. Wiemer
- Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut 06269-3092,United States
- Institute for Systems Genomics, University of Connecticut, Storrs, Connecticut 06269-3092, United States
| | - David F. Wiemer
- Department of Chemistry, University of Iowa, Iowa City, Iowa 52242-1294, United States
- Department of Pharmacology, University of Iowa, Iowa City, Iowa 52242-1109, United States
| |
Collapse
|
5
|
Gümüş M, Koca İ. Enamines and Dimethylamino Imines as Building Blocks in Heterocyclic Synthesis: Reactions of DMF‐DMA Reagent with Different Functional Groups. ChemistrySelect 2020. [DOI: 10.1002/slct.202002205] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Mehmet Gümüş
- Akdağmadeni Health College Yozgat Bozok University Yozgat Turkey
| | - İrfan Koca
- Department of Chemistry Faculty of Art & Sciences Yozgat Bozok University Yozgat Turkey
| |
Collapse
|
6
|
Agrawal N, Mishra P. The synthetic and therapeutic expedition of isoxazole and its analogs. Med Chem Res 2018; 27:1309-1344. [PMID: 32214770 PMCID: PMC7079875 DOI: 10.1007/s00044-018-2152-6] [Citation(s) in RCA: 85] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Accepted: 02/01/2018] [Indexed: 11/28/2022]
Abstract
Isoxazole, constituting an important family of five-membered heterocycles with one oxygen atom and one nitrogen atom at adjacent positions is of immense importance because of its wide spectrum of biological activities and therapeutic potential. It is, therefore, of prime importance that the development of new synthetic strategies and designing of new isoxazole derivatives should be based on the most recent knowledge emerging from the latest research. This review is an endeavor to highlight the progress in the chemistry and biological activity of isoxazole derivatives which could provide a low-height flying bird's eye view of isoxazole derivatives to the medicinal chemists for the development of clinically viable drugs using this information.
Collapse
Affiliation(s)
- Neetu Agrawal
- Institute of Pharmaceutical Research, GLA University, Mathura, U.P. India
| | - Pradeep Mishra
- Institute of Pharmaceutical Research, GLA University, Mathura, U.P. India
| |
Collapse
|
7
|
Jia H, Liu H, Guo Z, Huang J, Guo H. Tandem [3 + 2] Cycloaddition/1,4-Addition Reaction of Azomethine Ylides and Aza-o-quinone Methides for Asymmetric Synthesis of Imidazolidines. Org Lett 2017; 19:5236-5239. [DOI: 10.1021/acs.orglett.7b02512] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Hao Jia
- Department of Applied Chemistry, China Agricultural University, Beijing 100193, P. R. China
| | - Honglei Liu
- Department of Applied Chemistry, China Agricultural University, Beijing 100193, P. R. China
| | - Zhenyan Guo
- Department of Applied Chemistry, China Agricultural University, Beijing 100193, P. R. China
| | - Jiaxing Huang
- Department of Applied Chemistry, China Agricultural University, Beijing 100193, P. R. China
| | - Hongchao Guo
- Department of Applied Chemistry, China Agricultural University, Beijing 100193, P. R. China
| |
Collapse
|
8
|
Design, Synthesis and Biological Evaluation of Stilbene Derivatives as Novel Inhibitors of Protein Tyrosine Phosphatase 1B. Molecules 2016; 21:molecules21121722. [PMID: 27999292 PMCID: PMC6274251 DOI: 10.3390/molecules21121722] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Revised: 12/07/2016] [Accepted: 12/12/2016] [Indexed: 01/12/2023] Open
Abstract
By imitating the scaffold of lithocholic acid (LCA), a natural steroidal compound displaying Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, a series of stilbene derivatives containing phenyl-substituted isoxazoles were designed and synthesized. The structures of the title compounds were confirmed by 1H-NMR, 13C-NMR and HRMS. Activities of the title compounds were evaluated on PTP1B and the homologous enzyme TCPTP by using a colorimetric assay. Most of the target compounds had good activities against PTP1B. Among them, compound 29 (IC50 = 0.91 ± 0.33 μM), characterized by a 5-(2,3-dichlorophenyl) isoxazole moiety, exhibited an activity about 14-fold higher than the lead compound LCA and a 4.2-fold selectivity over TCPTP. Compound 29 was identified as a competitive inhibitor of PTP1B with a Ki value of 0.78 μM in enzyme kinetic studies.
Collapse
|
9
|
Monguchi Y, Kunishima K, Hattori T, Takahashi T, Shishido Y, Sawama Y, Sajiki H. Palladium-Catalyzed C–H Monoalkoxylation of α,β-Unsaturated Carbonyl Compounds. ACS Catal 2016. [DOI: 10.1021/acscatal.6b01084] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Yasunari Monguchi
- Laboratory
of Organic Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Kouki Kunishima
- Laboratory
of Organic Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Tomohiro Hattori
- Laboratory
of Organic Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Tohru Takahashi
- Laboratory
of Organic Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Yuko Shishido
- Laboratory
of Organic Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Yoshinari Sawama
- Laboratory
of Organic Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Hironao Sajiki
- Laboratory
of Organic Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| |
Collapse
|
10
|
Llona-Minguez S, Ghassemian A, Helleday T. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox. Prog Lipid Res 2015; 58:51-75. [DOI: 10.1016/j.plipres.2015.01.004] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2014] [Revised: 01/15/2015] [Accepted: 01/20/2015] [Indexed: 12/17/2022]
|
11
|
Yao L, Chai Y, Sun C, Pan Y. Competitive proton and hydride transfer reactions via ion-neutral complexes: fragmentation of deprotonated benzyl N-phenylcarbamates in mass spectrometry. JOURNAL OF MASS SPECTROMETRY : JMS 2015; 50:364-370. [PMID: 25800018 DOI: 10.1002/jms.3537] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Revised: 10/28/2014] [Accepted: 10/31/2014] [Indexed: 06/04/2023]
Abstract
The gas-phase chemistry of deprotonated benzyl N-phenylcarbamates was investigated by electrospray ionization tandem mass spectrometry. Characteristic losses of a substituted phenylcarbinol and a benzaldehyde from the precursor ion were proposed to be derived from an ion-neutral complex (INC)-mediated competitive proton and hydride transfer reactions. The intermediacy of the INC consisting of a substituted benzyloxy anion and a phenyl isocyanate was supported by both ortho-site-blocking experiments and density functional theory calculations. Within the INC, the benzyloxy anion played the role of either a proton abstractor or a hydride donor toward its neutral counterpart. Relative abundances of the product ions were influenced by the nature of the substituents. Electron-withdrawing groups at the N-phenyl ring favored the hydrogen transfer process (including proton and hydride transfer), whereas electron-donating groups favored direct decomposition to generate the benzyloxy anion (or substituted benzyloxy anion). By contrast, electron-withdrawing and electron-donating substitutions at the O-benzyl ring exhibited opposite effects.
Collapse
Affiliation(s)
- Liqing Yao
- Department of Chemistry, Zhejiang University, Hangzhou, 310027, Zhejiang, China
| | | | | | | |
Collapse
|
12
|
Qian Y, Hamilton M, Sidduri A, Gabriel S, Ren Y, Peng R, Kondru R, Narayanan A, Truitt T, Hamid R, Chen Y, Zhang L, Fretland AJ, Sanchez RA, Chang KC, Lucas M, Schoenfeld RC, Laine D, Fuentes ME, Stevenson CS, Budd DC. Discovery of Highly Selective and Orally Active Lysophosphatidic Acid Receptor-1 Antagonists with Potent Activity on Human Lung Fibroblasts. J Med Chem 2012; 55:7920-39. [DOI: 10.1021/jm301022v] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Yimin Qian
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Matthew Hamilton
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Achyutharao Sidduri
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Stephen Gabriel
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Yonglin Ren
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Ruoqi Peng
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Rama Kondru
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Arjun Narayanan
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Terry Truitt
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Rachid Hamid
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Yun Chen
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Lin Zhang
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Adrian J. Fretland
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Ruben Alvarez Sanchez
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Kung-Ching Chang
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Matthew Lucas
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Ryan C. Schoenfeld
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Dramane Laine
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Maria E. Fuentes
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - Christopher S. Stevenson
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| | - David C. Budd
- Discovery
Chemistry, ‡Discovery Inflammation and Respiratory Diseases, §Discovery Technology, ∥Pharmaceutical and
Analytical Research, and ⊥Drug Metabolism and Pharmacokinetics, Small Molecule Research, Pharmaceutical Research and Early Drug
Development, Hoffmann-La Roche, 340 Kingsland
Street, Nutley, New Jersey 07110, United States
| |
Collapse
|
13
|
Sato T, Sugimoto K, Inoue A, Okudaira S, Aoki J, Tokuyama H. Synthesis and biological evaluation of optically active Ki16425. Bioorg Med Chem Lett 2012; 22:4323-6. [PMID: 22658556 DOI: 10.1016/j.bmcl.2012.05.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2012] [Revised: 05/02/2012] [Accepted: 05/04/2012] [Indexed: 11/30/2022]
Abstract
An enantionselective synthesis of both enantiomers of Ki16425, which possesses selective LPA antagonistic activity, was achieved. The isoxazole core was constructed by a 1,3-dipolar cycloaddition of nitrile oxide with alkyne and condensation with the optically active α-phenethyl alcohol segment, which was prepared by an enantioselective reduction of arylmethylketone. Biological evaluation of both enantiomers of Ki16425 revealed that the (R)-isomer showed much higher antagonistic activity for LPA(1) and LPA(3) receptors.
Collapse
Affiliation(s)
- Takanao Sato
- Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba 6-3, Aramaki, Aoba-ku, Sendai 980-8578, Japan
| | | | | | | | | | | |
Collapse
|
14
|
Zhao JT, Qi JJ, Zhou YJ, Lv JG, Zhu J. Ethyl 5-(4-amino-phen-yl)isoxazole-3-carboxyl-ate. Acta Crystallogr Sect E Struct Rep Online 2012; 68:o1111. [PMID: 22589968 PMCID: PMC3344059 DOI: 10.1107/s1600536812010653] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2011] [Accepted: 03/10/2012] [Indexed: 11/23/2022]
Abstract
The asymmetric unit of the title compound, C12H12N2O3, contains two molecules in which the benzene and isoxazole rings are almost coplanar, the dihedral angles between their mean planes being 1.76 (9) and 5.85 (8)°. The two molecules interact with each other via N—H⋯N and N—H⋯O hydrogen bonds, which link the molecules into layers parallel to the ac plane. The layers stack in a parallel mode with an interlayer distance of 3.36 (7) Å.
Collapse
Affiliation(s)
- Jun-Tao Zhao
- Department of Medicinal Chemistry, School of Pharmacy, Second Military Medical University, Shanghai 200433, People's Republic of China
| | | | | | | | | |
Collapse
|
15
|
Badenock JC. Metalation Reactions of Isoxazoles and Benzisoxazoles. TOPICS IN HETEROCYCLIC CHEMISTRY 2012. [DOI: 10.1007/7081_2012_80] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
16
|
Gadzhily RA, Potkin VI, Aliev AG, Gadzhieva LY, Petkevich SK, Dikusar EA. Reaction of 3-alkyl(aryl)-5-chloromethylisoxazoles with nucleophilic reagents. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2011. [DOI: 10.1134/s1070428011100149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
17
|
Potkin VI, Petkevich SK, Kurman PV. Synthesis of 3-substitued 5-(2-thienyl)isoxazoles. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2011. [DOI: 10.1134/s1070428011060169] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
18
|
Structure and Magnetic Properties of A Novel Complex of Copper(II) Chloride With 3-(Hydroxyiminomethyl)-5-(2,5-Dimethylphenyl)Isoxazole. J STRUCT CHEM+ 2010. [DOI: 10.1007/s10947-010-0103-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
19
|
Roy B, De RN. Enhanced rate of intramolecular nitrile oxide cycloaddition and rapid synthesis of isoxazoles and isoxazolines. MONATSHEFTE FUR CHEMIE 2010. [DOI: 10.1007/s00706-010-0323-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
20
|
Potkin VI, Petkevich SK, Zalesskaya EG. Synthesis of functionally substituted isoxazoles from 5-(2,5-dimethylphenyl)-1,2-oxazole-3-carbonitrile. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2009. [DOI: 10.1134/s107042800906013x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
21
|
Singh V, Hutait S, Yadav GP, Maulik PR, Batra S. Unusual retention of isoxazole ring under the influence of 3-(substituted nitrophenyl)-2-isoxazoline during catalytic hydrogenation of isoxazoline-substituted isoxazole systems. J Heterocycl Chem 2009. [DOI: 10.1002/jhet.87] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
22
|
Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, Postlethwaite A, Watsky MA. Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009; 6:168-76. [PMID: 19521548 PMCID: PMC2695151 DOI: 10.7150/ijms.6.168] [Citation(s) in RCA: 107] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2009] [Accepted: 06/02/2009] [Indexed: 12/12/2022] Open
Abstract
Systemic sclerosis (SSc) is an often fatal disease characterized by autoimmunity and inflammation, leading to widespread vasculopathy and fibrosis. Lysophosphatidic acid (LPA), a bioactive phospholipid in serum, is generated from lysophospholipids secreted from activated platelets in part by the action of lysophospholipase D (lysoPLD). Sphingosine 1-phosphate (S1P), a member of the bioactive lysophospholipid family, is also released from activated platelets. Because activated platelets are a hallmark of SSc, we wanted to determine whether subjects with SSc have altered serum lysophospholipid levels or lysoPLD activity. Lysophospholipid levels were measured using mass spectrometric analysis. LysoPLD activity was determined by quantifying choline released from exogenous lysophosphatidylcholine (LPC). The major results were that serum levels of arachidonoyl (20:4)-LPA and S1P were significantly higher in SSc subjects versus controls. Furthermore, serum LPA:LPC ratios of two different polyunsaturated phospholipid molecular species, and also the ratio of all species combined, were significantly higher in SSc subjects versus controls. No significant differences were found between other lysophospholipid levels or lysoPLD activities. Elevated 20:4 LPA, S1P levels and polyunsaturated LPA:LPC ratios may be markers for and/or play a significant role in the etiology of SSc and may be future pharmacological targets for SSc treatment.
Collapse
Affiliation(s)
- Akira Tokumura
- Department of Health Chemistry, Institute of Health Bioscience, The University of Tokushima Graduate School, 1-78-1 Shomachi, Tokushima 770-8505, Japan
| | | | | | | | | | | | | |
Collapse
|
23
|
Li J, Xi H, Zhang J. 3-(10-Chloro-9-anthryl)-5-[3-(prop-2-ynyloxy)phenoxymethyl]isoxazole. Acta Crystallogr Sect E Struct Rep Online 2009; 65:o1401. [PMID: 21583246 PMCID: PMC2969672 DOI: 10.1107/s1600536809019229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2009] [Accepted: 05/21/2009] [Indexed: 11/10/2022]
Abstract
In the title molecule, C27H18ClNO3, the anthracene mean plane forms dihedral angles of 67.43 (2) and 15.75 (3)° with the isoxazole and benzene rings, respectively. In the crystal structure, C—H...π interactions link molecules into centrosymmetric dimers, which are further linked by weak intermolecular C—H...N hydrogen bonds into ribbons propagating in the [110] direction.
Collapse
|
24
|
Potkin VI, Petkevich SK, Kurman PV. Synthesis of 5-substituted 3-[5-(2,5-dimethylphenyl)-1,2-oxazol-3-yl]-1,2,4-oxadiazoles. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2009. [DOI: 10.1134/s1070428009040137] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
25
|
Zhang CY, Wang BL, Liu XH, Li YH, Wang SH, Li ZM. FACILE SYNTHESIS AND HERBICIDAL ACTIVITIES OF NEW ISOXAZOLE DERIVATIVES VIA 1,3-DIPOLAR CYCLO ADDITION REACTION. HETEROCYCL COMMUN 2008. [DOI: 10.1515/hc.2008.14.6.397] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
26
|
Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 2007; 9:1-18. [PMID: 17935635 DOI: 10.1017/s1462399407000476] [Citation(s) in RCA: 52] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The bioactive lipids lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), the enzymes that generate and degrade them, and the receptors that receive their signals are all potential therapeutic targets in cancer. LPA and S1P signalling pathways can modulate a range of cellular processes that contribute to tumourigenesis, such as proliferation and motility, and components of the signalling pathways often show aberrant expression and altered activity upon malignant transformation. This article reviews LPA- and S1P-mediated activities that might contribute to the aetiology of cancer, and examines the potential of the many antagonists that have been developed to inhibit LPA and S1P signalling pathways. In addition, the outcomes of various clinical trials using LPA- and S1P-associated targets in cancer and other diseases are described, and future directions are discussed.
Collapse
|